Haematologica (Dec 2013)

Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma

  • Fazila Asmar,
  • Vasu Punj,
  • Jesper Christensen,
  • Marianne T. Pedersen,
  • Anja Pedersen,
  • Anders B. Nielsen,
  • Christoffer Hother,
  • Ulrik Ralfkiaer,
  • Peter Brown,
  • Elisabeth Ralfkiaer,
  • Kristian Helin,
  • Kirsten Grønbæk

DOI
https://doi.org/10.3324/haematol.2013.088740
Journal volume & issue
Vol. 98, no. 12

Abstract

Read online

The discovery that the Ten-Eleven Translocation (TET) hydroxylases cause DNA demethylation has fundamentally changed the notion of how DNA methylation is regulated. Clonal analysis of the hematopoetic stem cell compartment suggests that TET2 mutations can be early events in hematologic cancers and recent investigations have shown TET2 mutations in diffuse large B-cell lymphoma. However, the detection rates and the types of TET2 mutations vary, and the relation to global methylation patterns has not been investigated. Here, we show TET2 mutations in 12 of 100 diffuse large B-cell lymphomas with 7% carrying loss-of-function and 5% carrying missense mutations. Genome-wide methylation profiling using 450K Illumina arrays identified 315 differentially methylated genes between TET2 mutated and TET2 wild-type cases. TET2 mutations are primarily associated with hypermethylation within CpG islands (70%; P